Logista Pharma and Neovii Strengthen Spanish Hospital Supply Chain for Grafalon®
Logista Pharma, the pharmaceutical distribution and integrated healthcare services division of Logista, has entered into a strategic collaboration agreement with Neovii, a biopharmaceutical company focused on immunosuppressive therapies for organ transplantation, haematology and oncology. The agreement will see Logista Pharma take responsibility for the distribution of Grafalon® across Spain, supporting the reliable supply of the specialised hospital treatment to healthcare centres.
The partnership represents an important step in the management of medicines that require highly controlled logistics, specialised storage and rapid delivery capabilities. Grafalon® is a specialised treatment used in combination with other immunosuppressive therapies for the prevention and treatment of acute rejection following solid organ transplantation. It is also used for the prevention of graft-versus-host disease following allogeneic haematopoietic stem cell transplantation.
Because of the specialised nature of the treatment and the requirements associated with its storage and distribution, the agreement places a strong emphasis on supply-chain reliability, temperature control, shipment traceability and responsiveness. Logista Pharma will manage the medicine’s supply chain in Spain through an integrated service designed to cover the different stages between procurement and delivery to hospitals.
Comprehensive Pharmaceutical Distribution Model
Under the terms of the agreement, Logista Pharma will provide Neovii with a complete 360-degree logistics service for Grafalon®. The model covers product procurement, specialised storage, order preparation, distribution to hospitals and invoicing to healthcare centres.
By combining these activities within a single operational framework, the service is designed to provide greater control over the movement of the medicine throughout the supply chain. For specialised hospital treatments, maintaining visibility across each stage of distribution is particularly important because healthcare centres need confidence that products can be supplied when required and handled according to their specific requirements.
The agreement also demonstrates the role of specialised pharmaceutical logistics providers in supporting manufacturers and biopharmaceutical companies. Rather than focusing only on transportation, Logista Pharma’s model brings together warehousing, inventory management, order fulfilment, distribution and monitoring capabilities.
For Neovii, this approach provides an integrated logistics structure for Grafalon® in the Spanish market. For Logista Pharma, the agreement further expands its involvement in hospital pharmaceutical distribution and reinforces its ability to manage products requiring specialised operational processes.
Supporting Access to a Critical Hospital Treatment
Grafalon® has more than four decades of clinical use and an international presence. The treatment represents an established option for medical teams involved in the management of transplant patients.
The distribution of a specialised hospital medicine requires more than simply moving products from one location to another. Availability, operational responsiveness and supply continuity can be important elements of the overall logistics process. Consequently, the distribution model established by Logista Pharma has been specifically designed around the requirements associated with Grafalon®.
The company will provide a service focused on maintaining availability in hospitals while ensuring that the product remains within the required conditions throughout the logistics chain.
The model includes capabilities for urgent deliveries, allowing the supply chain to respond to situations in which hospitals require rapid access to the treatment. At the same time, Logista Pharma will maintain traceability throughout the process, giving the parties involved greater visibility over individual shipments.
These capabilities are particularly relevant for specialised hospital products, where delivery requirements can be more demanding than those associated with conventional pharmaceutical distribution.
Strict Temperature-Control Requirements
One of the principal logistical requirements associated with Grafalon® is temperature control. The treatment must be maintained within a controlled temperature range of between 2°C and 8°C throughout the logistics process.
Maintaining this range requires specialised infrastructure and procedures covering storage, handling, preparation and transportation. Any cold-chain operation must account for the different stages of a shipment, from the moment a product leaves controlled storage through to its arrival at the hospital.
Logista Pharma will use its specialised pharmaceutical facilities to support these requirements. Its certified storage, handling and distribution processes are designed to manage products with high economic and therapeutic value and to maintain appropriate controls throughout the supply chain.
Temperature-controlled logistics is an important component of pharmaceutical distribution because storage and transportation conditions can directly affect how products are handled. For medicines requiring refrigerated conditions, logistics providers must therefore combine appropriate infrastructure with procedures that support consistency and traceability.
In the case of Grafalon®, the 2°C to 8°C requirement means that the supply-chain model must be structured around controlled conditions from the warehouse through to the final destination.
Nacex to Provide Express Delivery Capabilities
Transportation of Grafalon® to hospitals will be carried out through Nacex, Logista’s express courier network. The deliveries will use passive cold-chain solutions specifically designed to maintain the medicine’s required thermal conditions during transportation.
Passive cold-chain systems provide a controlled environment for temperature-sensitive pharmaceutical products during transit. In combination with suitable packaging, handling procedures and shipment monitoring, these solutions are intended to support the thermal stability of the product until it reaches the destination hospital.
The use of an express courier network also supports the responsiveness required for hospital deliveries. Pharmaceutical supply chains serving specialised treatments can require delivery solutions that are capable of responding quickly to individual orders and urgent requirements.
For Grafalon®, the transportation model therefore combines express distribution with temperature-controlled protection and shipment visibility.
End-to-End Traceability
Another important element of the agreement is the use of monitoring and traceability systems. These systems are designed to provide control over each shipment as it moves from Logista Pharma’s facilities to the destination healthcare centre.
Traceability is increasingly important across pharmaceutical supply chains because it provides visibility into the movement and handling of products. For specialised medicines, the ability to monitor shipments can help support operational control and coordination between logistics providers and healthcare centres.
Logista Pharma’s model incorporates advanced systems intended to maintain visibility throughout the delivery process. This complements the company’s specialised storage and handling capabilities and creates an integrated logistics framework for Grafalon®.
From procurement and warehousing through order preparation, transportation and hospital delivery, the service is designed to connect each stage of the distribution process.
Logista Pharma Expands Its Role in Specialised Healthcare Logistics
The agreement with Neovii further strengthens Logista Pharma’s presence in the hospital pharmaceutical sector. It also highlights the company’s capability to support products that require specialised storage, handling and distribution processes.
The pharmaceutical sector continues to place increasing importance on logistics capabilities that can accommodate complex supply requirements. Products with controlled-temperature requirements, high economic value or specialised handling procedures require infrastructure and operational expertise beyond conventional distribution.
Logista Pharma’s involvement in the Grafalon® supply chain demonstrates how an integrated logistics model can be applied to these requirements. By combining procurement, storage, order preparation, distribution and invoicing, the company provides a single service structure for Neovii’s Spanish operations involving the treatment.
The agreement also reinforces the importance of coordination between pharmaceutical manufacturers and logistics specialists. A biopharmaceutical company can rely on a dedicated distribution partner to manage the operational aspects of getting a specialised treatment from controlled storage to hospital facilities.
Focus on Reliability and Responsiveness
According to Ignacio Sánchez Caballero, General Manager of Logista Pharma Iberia, the distribution of Grafalon® illustrates the type of highly specialised operation in which the company aims to provide additional value.
He highlighted the critical nature of the medicine and the demanding requirements surrounding control, traceability and responsiveness. He also said the agreement strengthens Logista Pharma’s position as a strategic partner for pharmaceutical companies commercialising highly complex therapies.
The comments underline the operational demands associated with specialised pharmaceutical distribution. In these environments, logistics performance is measured not only by the speed of delivery but also by the ability to maintain product conditions and provide visibility throughout the process.
For Logista Pharma, the agreement therefore represents more than a conventional distribution arrangement. It provides an opportunity to apply its specialised infrastructure and healthcare logistics capabilities to a product with demanding supply-chain requirements.
Neovii’s Commitment to Supply Continuity
Neovii also emphasised the importance of maintaining reliable and uninterrupted access to Grafalon® for patients in Spain.
Frederic Prince, Chief Executive Officer of Neovii, said the agreement reflects the company’s commitment to ensuring dependable access to the treatment. He pointed to the importance of working with a specialised logistics partner capable of safeguarding quality, traceability and continuity of supply for transplant centres and the patients they serve.
The collaboration allows Neovii to work with Logista Pharma on a distribution structure specifically adapted to the requirements of the Spanish hospital market.
For healthcare centres, a dependable supply chain can provide greater confidence that specialised treatments will be available when required. At the same time, the use of controlled logistics processes helps maintain the conditions specified for the product throughout its movement through the distribution network.
Strengthening Hospital Pharmaceutical Distribution
The collaboration between Logista Pharma and Neovii comes as pharmaceutical distribution becomes increasingly specialised. Biopharmaceutical products and complex hospital therapies can require dedicated infrastructure, temperature management, shipment monitoring and specialised transportation solutions.
These requirements create a need for logistics providers that understand the operational characteristics of healthcare products and can build services around individual product requirements.
In the case of Grafalon®, the combination of specialised storage, 2°C to 8°C temperature control, passive cold-chain transportation, express delivery and end-to-end traceability creates a distribution model designed around the treatment’s specific logistics needs.
The agreement consequently adds another specialised operation to Logista Pharma’s healthcare distribution activities while giving Neovii an integrated supply-chain partner in Spain.
A Dedicated Model for Spanish Healthcare Centres
The Spanish distribution model will bring together several components of Logista’s wider logistics infrastructure. Procurement and storage will be managed through Logista Pharma’s specialised facilities, while deliveries will be supported by Nacex’s express courier network.
This integrated structure allows different stages of the supply chain to operate within a coordinated framework. It also supports the monitoring and traceability requirements associated with Grafalon®.
For hospitals and healthcare centres, the objective is to create a dependable delivery process capable of responding to standard and urgent requirements while maintaining the appropriate storage and transportation conditions.
The model also reflects the broader evolution of pharmaceutical logistics, where customers increasingly require services that combine physical distribution with data, monitoring and operational control.
Expanding Capabilities for Complex Medicines
For Logista Pharma, the agreement further demonstrates its ability to manage specialised biological and immunological medicines. These products can require carefully controlled conditions and detailed logistics procedures, making specialised pharmaceutical distribution an important part of their supply chains.
The company will use its facilities, certified processes and transportation capabilities to support the distribution of Grafalon® in Spain. The combination of controlled storage and passive cold-chain transportation is intended to maintain the required conditions throughout the product’s journey.
The agreement also highlights the importance of flexibility in healthcare logistics. The inclusion of urgent deliveries within the service model provides an additional level of responsiveness for hospital customers, while traceability systems provide visibility over individual shipments.
The partnership between Logista Pharma and Neovii establishes an integrated distribution framework for Grafalon® in Spain. Through the agreement, Logista Pharma will manage the treatment’s supply chain from procurement and specialised storage through order preparation, express transportation, hospital delivery and invoicing.
The service has been designed around the specific requirements of the medicine, including its 2°C to 8°C storage conditions, need for controlled handling and demand for comprehensive traceability.
Nacex’s express courier network will support transportation using passive cold-chain solutions, while Logista Pharma’s specialised facilities and monitoring systems will provide the infrastructure needed to manage the product throughout the distribution process.
For Neovii, the partnership provides a specialised logistics structure intended to support reliable and continuous supply to Spanish hospitals. For Logista Pharma, it represents another step in the expansion of its hospital distribution capabilities and its role as a strategic logistics partner for pharmaceutical companies handling complex therapies.
Ultimately, the collaboration illustrates how specialised pharmaceutical logistics can connect manufacturers with healthcare providers through controlled, traceable and responsive supply chains. By combining infrastructure, cold-chain capabilities, express transportation and end-to-end monitoring, Logista Pharma and Neovii aim to support the dependable distribution of Grafalon® to hospitals across Spain.
Source link: https://www.logista.com/